Regeneron Pharmaceuticals Inc. (REGN)

Cash Flow Statement
Quarterly Data

Difficulty: Beginner

The cash flow statement provides information about a company’s cash receipts and cash payments during an accounting period, showing how these cash flaws link the ending cash balance to the beginning balance shown on the company’s balance sheet.

The cash flow statement consists of three parts: cash flows provided by (used in) operating activities, cash flows provided by (used in) investing activities, and cash flows provided by (used in) financing activities.

Regeneron Pharmaceuticals Inc., consolidated cash flow statement (quarterly data)

US$ in thousands

	3 months ended	Jun 30, 2019		Mar 31, 2019		Dec 31, 2018		Sep 30, 2018		Jun 30, 2018		Mar 31, 2018		Dec 31, 2017		Sep 30, 2017		Jun 30, 2017		Mar 31, 2017		Dec 31, 2016		Sep 30, 2016		Jun 30, 2016		Mar 31, 2016		Dec 31, 2015		Sep 30, 2015		Jun 30, 2015		Mar 31, 2015		Dec 31, 2014		Sep 30, 2014		Jun 30, 2014		Mar 31, 2014
	Net income
	Depreciation and amortization
	Non-cash compensation expense
	Other non-cash items, net
	Deferred taxes
	(Increase) decrease in Sanofi, Bayer, and trade accounts receivable
	(Increase) decrease in inventories
	(Increase) decrease in prepaid expenses and other assets
	Increase (decrease) in deferred revenue
	Increase (decrease) in accounts payable, accrued expenses, and other liabilities
	Changes in assets and liabilities
	Adjustments to reconcile net income to net cash provided by (used in) operating activities
	Net cash provided by (used in) operating activities
	Purchases of marketable and other securities
	Sales or maturities of marketable securities
	Capital expenditures
	Other
	Net cash used in investing activities
	Proceeds in connection with capital and facility lease obligations
	Payments in connection with capital and facility lease obligations
	Proceeds (payments) in connection with capital and facility lease obligations
	Repayments of convertible senior notes
	Payments in connection with reduction of outstanding warrants
	Proceeds from issuance of Common Stock
	Payments in connection with Common Stock tendered for employee tax obligations
	Repurchases of Common Stock
	Excess tax benefit from stock-based compensation
	Net cash provided by (used in) financing activities
	Net increase (decrease) in cash, cash equivalents, and restricted cash

Cash flow statement item	Description	The company
Net cash provided by (used in) operating activities	Amount of cash inflow (outflow) from operating activities, excluding discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.	Regeneron Pharmaceuticals Inc.’s net cash provided by (used in) operating activities increased from Q4 2018 to Q1 2019 but then declined significantly from Q1 2019 to Q2 2019.
Net cash used in investing activities	Amount of cash inflow (outflow) of investing activities, excluding discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.	Regeneron Pharmaceuticals Inc.’s net cash used in investing activities declined from Q4 2018 to Q1 2019 and from Q1 2019 to Q2 2019.
Net cash provided by (used in) financing activities	Amount of cash inflow (outflow) of financing activities, excluding discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.	Regeneron Pharmaceuticals Inc.’s net cash provided by (used in) financing activities increased from Q4 2018 to Q1 2019 but then slightly declined from Q1 2019 to Q2 2019 not reaching Q4 2018 level.

	Regeneron Pharmaceuticals Inc.	Other companies (not purchased previously)
Financial Statements
Common-Size Financial Statements
Ratios
Relative Valuation
Discounted Cash Flow (DCF) Valuation
Economic Value Added (EVA)
Long-term Trends
Analysis
Financial Reporting Quality

	All companies
Financial Statements
Common-Size Financial Statements
Ratios
Relative Valuation
Discounted Cash Flow (DCF) Valuation
Economic Value Added (EVA)
Long-term Trends
Analysis
Financial Reporting Quality

Regeneron Pharmaceuticals Inc. (REGN)

Cash Flow StatementQuarterly Data

Cash Flow Statement
Quarterly Data